S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
"Prepare for Five Years of Famine" (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Will This Be the Worst U.S. Crisis Ever? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
"Prepare for Five Years of Famine" (Ad)
NASDAQ:NTRA

Natera - NTRA Stock Forecast, Price & News

$55.17
+1.58 (+2.95%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$53.49
$56.44
50-Day Range
$31.69
$55.29
52-Week Range
$26.10
$129.09
Volume
1.29 million shs
Average Volume
1.50 million shs
Market Capitalization
$5.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.50

Natera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
58.6% Upside
$87.50 Price Target
Short Interest
Healthy
6.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Natera in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$550,755 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.73) to ($4.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

257th out of 1,117 stocks

Medical Laboratories Industry

7th out of 28 stocks

NTRA stock logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $55.17 on Friday. The firm's 50 day simple moving average is $41.80 and its two-hundred day simple moving average is $45.10. The company has a quick ratio of 4.13, a current ratio of 3.58 and a debt-to-equity ratio of 0.63. Natera has a 1-year low of $26.10 and a 1-year high of $129.09.

Natera (NASDAQ:NTRA - Get Rating) last released its earnings results on Thursday, August 4th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($0.03). Natera had a negative return on equity of 95.97% and a negative net margin of 79.57%. The business had revenue of $198.20 million for the quarter, compared to analysts' expectations of $193.67 million. During the same quarter in the prior year, the business posted ($1.32) EPS. The business's revenue for the quarter was up 39.6% compared to the same quarter last year. On average, research analysts anticipate that Natera will post -5.73 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on NTRA. Stephens initiated coverage on shares of Natera in a report on Monday, April 25th. They issued an "overweight" rating and a $54.00 price objective on the stock. Cowen reduced their price objective on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Robert W. Baird dropped their target price on Natera from $100.00 to $71.00 in a report on Friday, May 6th. Cowen lowered their price target on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Finally, The Goldman Sachs Group cut their price objective on shares of Natera from $90.00 to $80.00 and set a "buy" rating on the stock in a research report on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $93.18.

Insider Activity at Natera

In related news, COO Robert Alan Schueren sold 572 shares of the business's stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $46.26, for a total value of $26,460.72. Following the sale, the chief operating officer now directly owns 572 shares in the company, valued at $26,460.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Natera news, COO Robert Alan Schueren sold 572 shares of Natera stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $46.26, for a total value of $26,460.72. Following the completion of the transaction, the chief operating officer now directly owns 572 shares of the company's stock, valued at approximately $26,460.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 1,652 shares of the stock in a transaction dated Thursday, June 23rd. The shares were sold at an average price of $35.76, for a total transaction of $59,075.52. Following the completion of the transaction, the chief executive officer now directly owns 64,777 shares of the company's stock, valued at approximately $2,316,425.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,966 shares of company stock valued at $550,755. Corporate insiders own 10.27% of the company's stock.

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Stock News Headlines

Natera Reports Second Quarter 2022 Financial Results
Natera, Inc. (NASDAQ:NTRA) CEO Sells $40,986.36 in Stock
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
2,670
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$87.50
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+58.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-471,720,000.00
Pretax Margin
-79.48%

Debt

Sales & Book Value

Annual Sales
$625.49 million
Book Value
$4.59 per share

Miscellaneous

Free Float
87,000,000
Market Cap
$5.35 billion
Optionable
Optionable
Beta
1.33














NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price forecast for 2022?

5 Wall Street research analysts have issued twelve-month price objectives for Natera's stock. Their NTRA share price forecasts range from $54.00 to $110.00. On average, they anticipate the company's share price to reach $87.50 in the next twelve months. This suggests a possible upside of 58.6% from the stock's current price.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2022?

Natera's stock was trading at $93.39 at the beginning of 2022. Since then, NTRA shares have decreased by 40.9% and is now trading at $55.17.
View the best growth stocks for 2022 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Thursday, August, 4th. The medical research company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.47) by $0.03. The medical research company had revenue of $198.20 million for the quarter, compared to analysts' expectations of $193.67 million. Natera had a negative trailing twelve-month return on equity of 95.97% and a negative net margin of 79.57%. The firm's quarterly revenue was up 39.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.32) earnings per share.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $805.00 million-$825.00 million, compared to the consensus revenue estimate of $805.18 million.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (5.64%), Pictet Asset Management SA (2.13%), Sculptor Capital LP (1.62%), Principal Financial Group Inc. (1.07%), Frontier Capital Management Co. LLC (0.92%) and Eagle Health Investments LP (0.59%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $55.17.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $5.35 billion and generates $625.49 million in revenue each year. The medical research company earns $-471,720,000.00 in net income (profit) each year or ($6.06) on an earnings per share basis.

How many employees does Natera have?

The company employs 2,670 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.